Market Drivers

Increasing Prevalence of Diabetes

Raw materials needed to manufacture such products The need and the marketability of such products are also backed up by the growing number of patient admissions globally that need monitoring of their blood on account of the fact that the prevalence of type 1 and type 2 diabetes is increasing in the number of patients affected both in the developed and the developing nations. Moreover, one of the greatest factors that have contributed to the escalating diabetes levels in developed and developing nations is the sedentary living tendency and the urbanization phenomenon. As an example, International Diabetes Federation (IDF) indicated that, in Europe, the current number of people with diabetes is 65.6 million by 2024, which will increase to 72.4 million by 2050. There has been a high prevalence in the number of individuals with diabetes-type 1 or insulin-dependent type 2 and this has been part of the world adoption of the blood glucose monitoring devices. Consequently, increasing cases of diabetes, increment of products in the market by large organizations and appropriate reimbursement policies are escalating the product demand and adoption hence increasing the growth of the global blood glucose monitoring system market.

Market Restraints

High Cost & Limited Reimbursement

Blood glucose monitoring systems have a disadvantage of being expensive and this poses a challenge in terms of adoption of these systems and especially continuous glucose monitoring (CGM) devices. In most underdeveloped countries, patients will foot the cost of the devices as they are not included in either the public or the commercial insurance policies. The criteria often require individuals with type 1 diabetes or with clinical requirements to be the only population that may receive coverage, which is also unsteady even in developed countries such as the United States and parts of Europe. This excludes a significant segment of the population that is stricken by type 2 diabetes and that can and will benefit because of continuous and early surveillance. The lack of full coverage hinders the SMBG-to-CGM transition and discourages it especially in low- and intermediate-income patients. The affordability and availability of glucose monitoring equipment are therefore still limited by cost and coverage gap.

By Device Type

In 2024, Continuous Blood Glucose Monitoring Devices Device Type has market share of 45.00% of market sales with market value of USD 6,338.45 Million.

The self-monitoring devices category had the dominance in the market in 2024 due to the ease of product accessibility, accessibility, and growing integration into daily routine and high technology development. The devices are also in high demand as the emphasis on preventative healthcare increases and as the trend toward personalized medicine grows higher. As technology continues to enhance, and as it expands into more areas concerning our health and medical conditions, self-monitoring devices will progress to even greater levels of health measuring capabilities and precision.

By Distribution Channel

In 2024, Retail Sales Distribution Channel has market share of 40.14% of market sales with market value of USD 5,654.51 Million.

In 2024, the retail sales segment prevailed in the market of blood glucose monitoring systems primarily due to the affiliated firms stepping up thematic strategic activities to expand their wireless presence in both developed and developing countries via drug stores, retail clinics, and stores on the internet. In their move to distribute products in the widest possible range, the top manufacturers focused on increasing their visibility and accessibility to customers by entering into distributive contracts with large retail chains and e-trading outlets where distribution time can be much shorter. The retail business benefitted more with the use of consumer education programs and promotional prices that helped it to stay in the top.

By Geography

North America dominates the Blood Glucose Monitoring System market with estimated market value of USD 6,197.57 Million in 2024, and is expected to reach USD 9,592.40 Million in 2032.

The increasing cases of diabetes, the mounting awareness about the uses of blood glucose monitors, the mounting preference of very advanced medical machinery, the mounting healthcare costs, and appropriate reimbursement initiatives are some of the significant forces that are stimulating the market. As an example, the data on the current number of people with diabetes in North America and the Caribbean (NAC) state that there are about 56.2 million individuals with diabetes in 2025 (based on the data published by the International Diabetes Federation (IDF)). That number will grow to 68.1 million adults by 2050.

List Of Top Players

• Abbott
• Braun SE
• Dexcom, Inc.
• Ascensia Diabetes Care Holdings AG
• Medtronic
• Hoffmann-La Roche Ltd
• Terumo Corporation
• LifeScan IP Holdings, LLC\
• Senseonics
• Insulet Corporation
• Ypsomed Holdings
• Glysens Incorporated
• Others

Key Industry Developments

• Also, in April 2025, S. FDA gave Dexcom approval to sell Dexcom G7 15-Day CGM to individuals aged 18 years and above with diabetes in the United States. This assisted the firm in boosting its brands.
• In August 2024, Dexcom marketed Stelo, an adult continuous glucose monitor that was accessible over-the-counter, in an attempt to consolidate its strength in the U.S.

Table of Contents

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. MARKET INTRODUCTION
   2. MARKET DRIVERS
   3. MARKET RESTRAINTS
   4. FUTURE OPPORTUNITIES
   5. MARKET TRENDS
   6. PORTER’S FIVE FORCES ANALYSIS
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Suppliers
      4. Bargaining Power of Buyers
      5. Intensity of Competitive Rivalry
   7. VALUE CHAIN & PROFIT MARGIN ANALYSIS
   8. PRICING ANALYSIS
   9. REGULATORY FRAMEWORK
   10. COVID-19 IMPACT ANALYSIS
   11. PRODUCT LIFE CYCLE ANALYSIS
   12. PESTLE ANALYSIS
   13. MICRO ECONOMIC ANALYSIS
   14. Market Premium Insights (Enterprise license)
       • Consumer Analysis (List of Potential Consumers)
       • Top 10 Country-Wise Import & Export Data (If Applicable)
       • Regulatory Bodies & Authorization Across the Globe
       • Key Conferences & Events: Next Two Years
       • Top Patents for The Market
5. GLOBAL BLOOD GLUCOSE MONITORING SYSTEM MARKET REVENUE & SHARE ANALYSIS (2023-2032)
   1. By Device Type
      1. Self-Monitoring Blood Glucose System
      2. Continuous Blood Glucose Monitoring Devices
   2. By Modality 
      1. Non-Wearable
      2. Wearable
   3. By Distribution Channel 
      1. Retail Sales
      2. Institutional Sales
      3. Others 
   4. By Patient Type 
      1. Type 1 diabetes
      2. Type 2 diabetes 
6. GLOBAL BLOOD GLUCOSE MONITORING SYSTEM MARKET REVENUE & SHARE ANALYSIS (2023-2032), BY REGION
   1. NORTH AMERICA 
      1. U.S.
      2. Canada
      3. Mexico
   2. EUROPE
      1. Germany
      2. UK
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
   3. ASIA PACIFIC 
      1. China
      2. Japan
      3. India
      4. South Korea
      5. Rest of APAC
   4. MIDDLE EAST & AFRICA
      1. GCC
      2. South Africa
      3. Rest of MEA
   5. LATIN AMERICA
      1. Brazil
      2. Argentina
      3. Rest of LATAM

For all the segments and sub-segments, Qualitative as well as Quantitative data will be provided. In Quantitative we provide the historic (2023), base (2024), estimated (2025) and forecasted (2025-2032) market value in USD Million, Share in XX% with a CAGR (2025-2032). This data would be provided on a regional as well as country level.

1. COMPETITIVE LANDSCAPE
   1. OVERVIEW
   2. KEY PLAYERS MARKET SHARE ANALYSIS
   3. LIST OF KEY STRATEGIC DEVELOPMENTS 
2. COMPANY PROFILES
   1. Abbott
      1. Company Overview
      2. Company Financial Insights (Total Revenue, Revenue By Business Segments, and By Region)
      3. Product Benchmarking
      4. Key Strategic Developments (Merges & Acquisitions, Partnership /Agreements/Joint Venture, Expansion, New Product Launches, and other developments)
      5. Business Strategic Overview
      6. SWOT Analysis
   2. Braun SE
   3. Dexcom, Inc.
   4. Ascensia Diabetes Care Holdings AG
   5. Medtronic
   6. Hoffmann-La Roche Ltd
   7. Terumo Corporation
   8. LifeScan IP Holdings, LLC
   9. Senseonics
   10. Insulet Corporation
   11. Ypsomed Holdings
   12. Glysens Incorporated
   13. Others
3. LIST OF SOURCES

DISCLAIMER